← Leaderboards
Nikhil C. Munshi
Va Boston Health Care System
$16,726,757
Attributed
$16,726,757
Total exposure
19
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.9M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$55,805,474 · 18
VA$0 · 3
By mechanism
P01$35,382,203 · 11
P50$18,670,436 · 6
R01$1,752,835 · 1
I01$0 · 1
IS1$0 · 2
Top collaborators
- Kenneth C Anderson5 shared
Others in their field
Top investigators on “Multiple Myeloma”
- David Heimbrook · Leidos Biomedical Research, Inc.$146,380,351
- Larry Arthur$41,717,333
- Charles A Coltman · Southwest Oncology Group$36,988,659
- Kenneth C Anderson · Dana-Farber Cancer Inst$25,497,347
- Irene M. Ghobrial · Dana-Farber Cancer Inst$22,402,686
- Nilsa Del Carmen Ramirez · Ohio State University$22,287,552
Research focus
Multiple MyelomaMolecularCellsGenomicsGenomic InstabilitySamplingFundingClinical ResearchResponseDiagnosisClinical TrialsCancer GenomicsProgramsInvestigationNovel TherapeuticsResearch PersonnelDisease ProgressionPathway InteractionsMutationBaseMalignant NeoplasmsDoseAutomobile DrivingIn Vitro
Grant awards (100)
Integrative Oncogenomics of Multiple Myeloma$2,239,580
P01 · FY2025 · CA · contact PI
Project 4: Targeting genomic instability and evolution in myeloma$259,299
P01 · FY2025 · CA · contact PI
Core 1: Administrative Core$184,175
P01 · FY2025 · CA · contact PI
Integrative Oncogenomics of Multiple Myeloma$161,714
P01 · FY2025 · CA · contact PI
Molecular Manipulation to Enhance Anti-Myeloma Response$0
I01 · FY2025 · VA · contact PI
Integrative Oncogenomics of Multiple Myeloma$2,281,230
P01 · FY2024 · CA · contact PI
Project 4: Targeting genomic instability and evolution in myeloma$240,658
P01 · FY2024 · CA · contact PI
Core 1: Administrative Core$196,207
P01 · FY2024 · CA · contact PI
Molecular Manipulation to Enhance Anti-Myeloma Response$0
I01 · FY2024 · VA · contact PI
Integrative Oncogenomics of Multiple Myeloma$2,498,796
P01 · FY2023 · CA · contact PI
SPORE in Multiple Myeloma$2,257,199
P50 · FY2023 · CA
Targeting AP Nuclease, a Mediator of Genomic Instability in MM$406,596
P50 · FY2023 · CA · contact PI
Project 4: Targeting genomic instability and evolution in myeloma$313,545
P01 · FY2023 · CA · contact PI
Tissue Banking Core$234,915
P50 · FY2023 · CA · contact PI
Core 1: Administrative Core$234,422
P01 · FY2023 · CA · contact PI
Molecular Manipulation to Enhance Anti-Myeloma Response$0
I01 · FY2023 · VA · contact PI
SPORE in Multiple Myeloma$2,257,199
P50 · FY2022 · CA
Targeting AP Nuclease, a Mediator of Genomic Instability in MM$406,596
P50 · FY2022 · CA · contact PI
Tissue Banking Core$234,916
P50 · FY2022 · CA · contact PI
SPORE in Multiple Myeloma$2,257,199
P50 · FY2021 · CA
Integrative Oncogenomics of Multiple Myeloma$2,065,928
P01 · FY2021 · CA · contact PI
Targeting AP Nuclease, a Mediator of Genomic Instability in MM$437,200
P50 · FY2021 · CA · contact PI
Project 4. Targeting genomic instability and evolution in myeloma$280,767
P01 · FY2021 · CA · contact PI
Tissue Banking Core$252,596
P50 · FY2021 · CA · contact PI
Core 1: Administrative and Communication Core$229,796
P01 · FY2021 · CA · contact PI
Molecular Manipulation to Enhance Anti-Myeloma Response$0
I01 · FY2021 · VA · contact PI
SPORE in Multiple Myeloma$2,349,611
P50 · FY2020 · CA
Integrative Oncogenomics of Multiple Myeloma$2,065,928
P01 · FY2020 · CA · contact PI
Targeting AP Nuclease, a Mediator of Genomic Instability in MM$427,515
P50 · FY2020 · CA · contact PI
Project 4. Targeting genomic instability and evolution in myeloma$280,767
P01 · FY2020 · CA · contact PI
Tissue Banking Core$242,911
P50 · FY2020 · CA · contact PI
Core 1: Administrative and Communication Core$229,796
P01 · FY2020 · CA · contact PI
Molecular Manipulation to Enhance Anti-Myeloma Response$0
I01 · FY2020 · VA · contact PI
SPORE in Multiple Myeloma$2,276,698
P50 · FY2019 · CA
Integrative Oncogenomics of Multiple Myeloma$2,065,928
P01 · FY2019 · CA · contact PI
Targeting AP Nuclease, a Mediator of Genomic Instability in MM$406,596
P50 · FY2019 · CA · contact PI
Project 4. Targeting genomic instability and evolution in myeloma$280,769
P01 · FY2019 · CA · contact PI
Tissue Banking Core$254,414
P50 · FY2019 · CA · contact PI
Core 1: Administrative and Communication Core$229,794
P01 · FY2019 · CA · contact PI
ShEEP request for next generation sequencing system$0
IS1 · FY2019 · VA · contact PI
Molecular Manipulation to Enhance Anti-Myeloma Response$0
I01 · FY2019 · VA · contact PI
Integrative Oncogenomics of Multiple Myeloma$2,065,928
P01 · FY2018 · CA · contact PI
Project 4. Targeting genomic instability and evolution in myeloma$280,767
P01 · FY2018 · CA · contact PI
Integrative Oncogenomics of Multiple Myeloma (1 of 2)$264,750
P01 · FY2018 · CA · contact PI
Core 1: Administrative and Communication Core$229,796
P01 · FY2018 · CA · contact PI
Integrative Oncogenomics of Multiple Myeloma (2 of 2)$88,250
P01 · FY2018 · CA · contact PI
Core 1: Administrative and Communication Core$29,417
P01 · FY2018 · CA · contact PI
Project 4. Targeting genomic instability and evolution in myeloma$29,416
P01 · FY2018 · CA · contact PI
Core 1: Administrative and Communication Core$9,806
P01 · FY2018 · CA · contact PI
Project 4. Targeting genomic instability and evolution in myeloma$9,805
P01 · FY2018 · CA · contact PI
Molecular Manipulation to Enhance Anti-Myeloma Response$0
I01 · FY2018 · VA · contact PI
Integrative Oncogenomics of Multiple Myeloma$2,086,676
P01 · FY2017 · CA · contact PI
Targeting Genomic Instability in Multiple Myeloma$318,410
P50 · FY2017 · CA · contact PI
Tissue Banking Core$307,641
P50 · FY2017 · CA · contact PI
Project 4. Targeting genomic instability and evolution in myeloma$283,713
P01 · FY2017 · CA · contact PI
Core 1: Administrative and Communication Core$231,911
P01 · FY2017 · CA · contact PI
ShEEP Request for BD FACSAria Fusion Cell Sorting Flow Cytometer$0
IS1 · FY2017 · VA · contact PI
Targeting Genomic Instability in Multiple Myeloma$296,352
P50 · FY2016 · CA · contact PI
Tissue Banking Core$286,734
P50 · FY2016 · CA · contact PI
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE$0
I01 · FY2016 · VA · contact PI
Integrative Oncogenomics of Multiple Myeloma$1,988,528
P01 · FY2015 · CA · contact PI
Targeting Genomic Instability in Multiple Myeloma$299,505
P50 · FY2015 · CA · contact PI
Tissue Banking Core$289,784
P50 · FY2015 · CA · contact PI
Targeting Genomic Instability and Evolution in Myeloma$205,369
P01 · FY2015 · CA · contact PI
Administrative and Communication Core$168,509
P01 · FY2015 · CA · contact PI
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE$0
I01 · FY2015 · VA · contact PI
Integrative Oncogenomics of Multiple Myeloma$1,932,302
P01 · FY2014 · CA · contact PI
Innate and Adaptive Anti-Myeloma Immunity$361,924
P01 · FY2014 · CA · contact PI
Targeting Genomic Instability in Multiple Myeloma$296,416
P50 · FY2014 · CA · contact PI
Tissue Banking Core$286,796
P50 · FY2014 · CA · contact PI
Targeting Genomic Instability and Evolution in Myeloma$199,938
P01 · FY2014 · CA · contact PI
Administrative and Communication Core$164,165
P01 · FY2014 · CA · contact PI
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE$0
I01 · FY2014 · VA · contact PI
Integrative Oncogenomics of Multiple Myeloma$1,875,926
P01 · FY2013 · CA · contact PI
Innate and Adaptive Anti-Myeloma Immunity$328,732
P01 · FY2013 · CA · contact PI
Targeting Genomic Instability in Multiple Myeloma$292,214
P50 · FY2013 · CA · contact PI
Tissue Banking Core$282,731
P50 · FY2013 · CA · contact PI
Targeting Genomic Instability and Evolution in Myeloma$193,582
P01 · FY2013 · CA · contact PI
Administrative and Communication Core$156,691
P01 · FY2013 · CA · contact PI
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE$0
I01 · FY2013 · VA · contact PI
Integrative Oncogenomics of Multiple Myeloma$1,999,347
P01 · FY2012 · CA · contact PI
Innate and Adaptive Anti-Myeloma Immunity$377,027
P01 · FY2012 · CA · contact PI
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma$344,180
R01 · FY2012 · CA · contact PI
P-2: Targeting telomerase expansion mechanism in MM$216,113
P50 · FY2012 · CA · contact PI
Targeting Genomic Instability and Evolution in Myeloma$207,670
P01 · FY2012 · CA · contact PI
Administrative and Communication Core$170,759
P01 · FY2012 · CA · contact PI
Integrative Oncogenomics of Multiple Myeloma$2,000,000
P01 · FY2011 · CA · contact PI
Innate and Adaptive Anti-Myeloma Immunity$377,781
P01 · FY2011 · CA · contact PI
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma$344,180
R01 · FY2011 · CA · contact PI
Targeting Genomic Instability and Evolution in Myeloma$254,355
P01 · FY2011 · CA · contact PI
Administrative and Communication Core$209,187
P01 · FY2011 · CA · contact PI
P-2: Targeting telomerase expansion mechanism in MM$206,386
P50 · FY2011 · CA · contact PI
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma$354,825
R01 · FY2010 · CA · contact PI
Innate and Adaptive Anti-Myeloma Immunity$261,077
P01 · FY2010 · CA · contact PI
P-2: Targeting telomerase expansion mechanism in MM$216,629
P50 · FY2010 · CA · contact PI
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma$354,825
R01 · FY2009 · CA · contact PI
P-2: Targeting telomerase expansion mechanism in MM$215,872
P50 · FY2009 · CA · contact PI
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma$354,825
R01 · FY2008 · CA · contact PI
P-2: Targeting telomerase expansion mechanism in MM$156,692
P50 · FY2008 · CA · contact PI
DEVELOPMENTAL THERAPEUTICS$0
P01 · FY2000 · CA